Bladder cancer: Research is driving new treatment options, better ...
WEBMay 22, 2024 · Dr. Mark Tyson discusses new and developing bladder cancer treatment options and what you should know when seeking bladder cancer care.
New combination treatment brings hope to patients with advanced bladder …
WEB1 day ago · Credit: JAMA Oncology (2024). DOI: 10.1001/jamaoncol.2024.3900. Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and ...
Pembrolizumab improves outcomes in high-risk bladder cancer
WEB5 days ago · NCI Press Office. 240-760-6600. Adjuvant pembrolizumab helps people with muscle-invasive bladder cancer remain cancer-free longer than observation alone. Credit: Terese Winslow/National Cancer Institute. Results from a large clinical trial show that treatment with an immunotherapy drug may nearly …
Bladder cancer: What you should know about diagnosis, …
WEBMay 30, 2023 · Bladder cancer is one of the most common cancer types in the U.S., according to the National Cancer Institute. It's also one of the most likely types of cancer to recur. Experts are developing ways to reduce bladder cancer recurrence, and, with treatments and follow-up care tailored to each person’s cancer, outcomes are improving.
New ways to treat bladder cancer improve survival and shake up …
WEBOct 23, 2023 · CNN — A new combination of cancer medications appears to extend overall survival in patients with advanced bladder cancer more than the chemotherapies currently used as the standard of care.
Immunotherapy after surgery helps people with high-risk bladder cancer ...
WEB4 days ago · They randomly assigned 702 patients with high-risk, muscle-invasive bladder cancer who had undergone bladder-removal surgery to receive adjuvant therapy with pembrolizumab every three weeks for a year, or to observation for the same period of time. About two-thirds of the patients in the trial had completed neoadjuvant therapy …
Padcev and Keytruda Double Bladder Cancer Survival - NCI
WEBNov 30, 2023 · For people with advanced bladder cancer, combining enfortumab (Padcev) and pembrolizumab (Keytruda) should be the new standard initial treatment, new clinical trial results suggest.
Innovative combination therapy shows promise for bladder cancer ...
WEBJun 6, 2024 · In a groundbreaking advance that could revolutionize bladder cancer treatment, a novel combination of cretostimogene grenadenorepvec and pembrolizumab has shown remarkable efficacy in patients with...
New Metastatic Bladder Cancer Therapy Approved by FDA: …
WEBApr 10, 2023 · The U.S. Food and Drug Administration (FDA) on April 3 approved enfortumab vedotin (Padcev®) plus the immunotherapy drug pembrolizumab (Keytruda®) for people newly diagnosed with metastatic urothelial carcinoma — a cancer that primarily arises in the bladder and also occurs in other parts of the urinary system.
FDA approves new, targeted treatment for bladder cancer
WEBThe U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma.